Biotech entity

DePuy Synthes

Company

pharma is the sole category represented across all 1 tracked stories. DePuy Synthes is most often covered alongside Bank of America, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.

Last mentioned: Mar 12, 2026

Entity pulse

Recent coverage · DePuy Synthes

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about DePuy Synthes

pharma is the sole category represented across all 1 tracked stories. DePuy Synthes is most often covered alongside Bank of America, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window. We currently track 1 Biotech story that mention DePuy Synthes, all published on March 12, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering DePuy Synthes. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. BofA Price Target Hike

    Bank of America increases price target, highlighting R&D productivity and MedTech growth.

  2. Fast-Track Approval

    USFDA grants approval for Tecvayli-Darzalex combination via fast-track voucher program.

  3. 12-Month High

    JNJ shares reach a new yearly peak following FDA approval for multiple myeloma combo.

Stories mentioning DePuy Synthes 1

Pharma Neutral

BofA Bullish on Johnson & Johnson as Pipeline Momentum Accelerates

Bank of America has raised its price target for Johnson & Johnson, citing a robust outlook for the company's Innovative Medicine and MedTech divisions. The upgrade reflects growing confidence in JNJ's oncology pipeline and its ability to navigate upcoming patent expirations for key assets.

2 sources

DePuy Synthes is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.